Premium
Hepatosplenic T ‐cell lymphoma, immunosuppressive agents and biologicals: what are the risks?
Author(s) -
Subramaniam K.,
Yeung D.,
Grimpen F.,
Joseph J.,
Fay K.,
Buckland M.,
Talaulikar D.,
Elijah J.,
Clarke A. C.,
Pavli P.,
Moore J.
Publication year - 2014
Publication title -
internal medicine journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.596
H-Index - 70
eISSN - 1445-5994
pISSN - 1444-0903
DOI - 10.1111/imj.12363
Subject(s) - medicine , azathioprine , etanercept , methotrexate , psoriasis , lymphoma , pharmacovigilance , biosimilar , dermatology , immunology , disease , rheumatoid arthritis , drug , pharmacology
We present three cases of the rare hepatosplenic T ‐cell lymphoma ( HSTCL ); two patients suffering from C rohn disease who developed HSTCL on azathioprine without exposure to biologicals, and a third patient who had psoriasis treated using etanercept, cyclosporine and methotrexate. The evidence for an association between HSTCL and immunosuppressive drugs and biologicals is reviewed. We argue for improved pharmacovigilance processes to help determine the benefit to risk ratios for the use of these and other new agents.